Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
324 results
  • Tattoo complications in treated and non-treated psoriatic patients. [Journal Article]
    J Eur Acad Dermatol Venereol 2019Grodner C, Beauchet A, … GEM Resopso
  • CONCLUSIONS: The rate of tattoo complications in psoriasis patients was low. Although the risk of complications was highest amongst patients with psoriasis requiring treatment at the time of tattooing, all the complications observed were benign. These results can be helpful for practitioners to give objective information to patients.
  • Erythroderma and Chronic Lichenification Due to Metformin. [Journal Article]
    Eur J Case Rep Intern Med 2019; 6(6):001119Díaz JM, Bruñén JMG, … González AM
  • We present the case of a 62-year-old man with a 4-year history of pruritus and erythroderma. The patient had been taking metformin for 5 years, so after contact allergies, contact with toxic products, and autoimmune diseases were ruled out, the condition was treated as erythroderma secondary to metformin. A skin biopsy subsequently confirmed the diagnosis and lichenification of some areas of the …
  • Atopic Dermatitis-Like Rash During Evolocumab Treatment of Familial Hypercholesterolemia. [Journal Article]
    J Nippon Med Sch 2019; 86(3):187-190Kanda N, Okajima F
  • Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that targets the low-density lipoprotein (LDL) receptor for lysosomal degradation. PCSK9 impedes the receptor-mediated clearance of LDL-cholesterol, thereby increasing serum LDL-cholesterol levels. Evolocumab, a human monoclonal antibody against PCSK9, effectively reduces serum LDL-cholesterol levels. We report the first k…
  • Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis. [Review]
    Dermatol Ther (Heidelb) 2019; 9(3):407-420Smith MP, Ly K, … Liao W
  • CONCLUSIONS: The variety of new and improved methods to evaluate pruritus in AD is welcomed by clinicians, researchers, and patients alike. Future directions include next-generation smart devices as well as exploring new territories, such as identifying biomarkers that correlate to itch and machine-learning programs to identify itch processing in the brain. As these efforts continue, it will be essential to remain patient-centered by developing techniques that minimize discomfort, respect privacy, and provide accurate data that can be used to better manage itch in AD.
New Search Next